These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37935033)

  • 1. Leptin Reduction as a Required Component for Weight Loss.
    Zhao S; Li N; Xiong W; Li G; He S; Zhang Z; Zhu Q; Jiang N; Ikejiofor C; Zhu Y; Wang MY; Han X; Zhang N; Solis-Herrera C; Kusminski C; An Z; Elmquist JK; Scherer PE
    Diabetes; 2024 Feb; 73(2):197-210. PubMed ID: 37935033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets.
    Le TDV; Fathi P; Watters AB; Ellis BJ; Besing GK; Bozadjieva-Kramer N; Perez MB; Sullivan AI; Rose JP; Baggio LL; Koehler J; Brown JL; Bales MB; Nwaba KG; Campbell JE; Drucker DJ; Potthoff MJ; Seeley RJ; Ayala JE
    Mol Metab; 2023 Jun; 72():101718. PubMed ID: 37030441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
    Mashayekhi M; Nian H; Mayfield D; Devin JK; Gamboa JL; Yu C; Silver HJ; Niswender K; Luther JM; Brown NJ
    Diabetes; 2024 Jan; 73(1):38-50. PubMed ID: 37874653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice.
    Akindehin S; Liskiewicz A; Liskiewicz D; Bernecker M; Garcia-Caceres C; Drucker DJ; Finan B; Grandl G; Gutgesell R; Hofmann SM; Khalil A; Liu X; Cota P; Bakhti M; Czarnecki O; Bastidas-Ponce A; Lickert H; Kang L; Maity G; Novikoff A; Parlee S; Pathak E; Schriever SC; Sterr M; Ussar S; Zhang Q; DiMarchi R; Tschöp MH; Pfluger PT; Douros JD; Müller TD
    Mol Metab; 2024 May; 83():101915. PubMed ID: 38492844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss.
    Iepsen EW; Lundgren J; Dirksen C; Jensen JE; Pedersen O; Hansen T; Madsbad S; Holst JJ; Torekov SS
    Int J Obes (Lond); 2015 May; 39(5):834-41. PubMed ID: 25287751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge.
    Liu D; Pang J; Shao W; Gu J; Zeng Y; He HH; Ling W; Qian X; Jin T
    Hepatology; 2021 Oct; 74(4):2154-2169. PubMed ID: 33851458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice.
    Burmeister MA; Ayala JE; Smouse H; Landivar-Rocha A; Brown JD; Drucker DJ; Stoffers DA; Sandoval DA; Seeley RJ; Ayala JE
    Diabetes; 2017 Feb; 66(2):372-384. PubMed ID: 27908915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
    Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 receptor activation stimulates PKA-mediated phosphorylation of Raptor and this contributes to the weight loss effect of liraglutide.
    Le TDV; Liu D; Besing GK; Raghavan R; Ellis BJ; Ceddia RP; Collins S; Ayala JE
    Elife; 2023 Nov; 12():. PubMed ID: 37930356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.
    Pickford P; Lucey M; Rujan RM; McGlone ER; Bitsi S; Ashford FB; Corrêa IR; Hodson DJ; Tomas A; Deganutti G; Reynolds CA; Owen BM; Tan TM; Minnion J; Jones B; Bloom SR
    Mol Metab; 2021 Sep; 51():101242. PubMed ID: 33933675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile.
    Larsen AT; Gydesen S; Sonne N; Karsdal MA; Henriksen K
    BMC Endocr Disord; 2021 Jan; 21(1):10. PubMed ID: 33413317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver Fibroblast Growth Factor 21 (FGF21) is Required for the Full Anorectic Effect of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide in Male Mice fed High Carbohydrate Diets.
    Le TDV; Fathi P; Watters AB; Ellis BJ; Bozadjieva-Kramer N; Perez MB; Sullivan AI; Rose JP; Baggio LL; Koehler J; Brown JL; Bales MB; Nwaba KG; Campbell JE; Drucker DJ; Potthoff MJ; Seeley RJ; Ayala JE
    bioRxiv; 2023 Jan; ():. PubMed ID: 36711605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
    Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
    Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The gut microbiota regulates hypothalamic inflammation and leptin sensitivity in Western diet-fed mice via a GLP-1R-dependent mechanism.
    Heiss CN; Mannerås-Holm L; Lee YS; Serrano-Lobo J; Håkansson Gladh A; Seeley RJ; Drucker DJ; Bäckhed F; Olofsson LE
    Cell Rep; 2021 May; 35(8):109163. PubMed ID: 34038733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism.
    West JA; Tsakmaki A; Ghosh SS; Parkes DG; Grønlund RV; Pedersen PJ; Maggs D; Rajagopalan H; Bewick GA
    PLoS One; 2021; 16(3):e0249239. PubMed ID: 33788878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice.
    He M; Su H; Gao W; Johansson SM; Liu Q; Wu X; Liao J; Young AA; Bartfai T; Wang MW
    PLoS One; 2010 Dec; 5(12):e14205. PubMed ID: 21151924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice.
    Frikke-Schmidt H; Hultman K; Galaske JW; Jørgensen SB; Myers MG; Seeley RJ
    Mol Metab; 2019 Mar; 21():13-21. PubMed ID: 30685336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice.
    Clemmensen C; Finan B; Fischer K; Tom RZ; Legutko B; Sehrer L; Heine D; Grassl N; Meyer CW; Henderson B; Hofmann SM; Tschöp MH; Van der Ploeg LH; Müller TD
    EMBO Mol Med; 2015 Mar; 7(3):288-98. PubMed ID: 25652173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocannabinoid-related molecules predict the metabolic efficacy of GLP-1 receptor agonism in humans with obesity.
    Matias I; Lehmann EW; Zizzari P; Byberg S; Cota D; Torekov SS; Quarta C
    J Endocrinol Invest; 2024 May; 47(5):1289-1294. PubMed ID: 37924474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction.
    Pastel E; McCulloch LJ; Ward R; Joshi S; Gooding KM; Shore AC; Kos K
    Clin Sci (Lond); 2017 Mar; 131(5):343-353. PubMed ID: 28049736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.